• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immuneering Corp Cl A (NQ: IMRX )

    1.870 +0.010 (+0.54%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 152,635
    Open 1.880
    Bid (Size) 1.870 (5)
    Ask (Size) 1.910 (5)
    Prev. Close 1.860
    Today's Range 1.841 - 1.949
    52wk Range 1.000 - 8.890
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga

    Performance

    YTD
    -74.45%
    -74.45%
    1 Month
    -21.10%
    -21.10%
    3 Month
    +53.28%
    +53.28%
    6 Month
    +13.33%
    +13.33%
    1 Year
    -68.83%
    -68.83%

    More News

    Read More
    Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
    From Immuneering Corporation
    Via GlobeNewswire
    EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
    Via Benzinga
    Why is Immuneering (IMRX) Stock Up 24% Today?
    Via InvestorPlace
    Why Is Nanocap Immuneering Stock Trading Higher On Friday?
    Via Benzinga
    Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From Immuneering Corporation
    Via GlobeNewswire
    Nasdaq Surges 1%; Meta Posts Upbeat Earnings
    Via Benzinga
    Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
    From Immuneering Corporation
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Immuneering to Present at the Jefferies Global Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
    Via InvestorPlace
    Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Recognizes Melanoma Awareness Month
    From Immuneering Corporation
    Via GlobeNewswire
    IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
    From Immuneering Corporation
    Via GlobeNewswire
    3 Stocks Insiders Are Buying That Analysts Love
    Via MarketBeat
    March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
    Via AB Newswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.